British Society for Rheumatology

Rheumatoid Arthritis Register

MANCHESTER 1824

The University of Manchester

British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA)

Monitoring the long-term safety of biologic, biosimilar, and other new targeted therapies in the UK.

Over 30,000 patients registered in the study since 2001.

NEW REGISTRATIONS AND FOLLOW-UP DATA IS SUBMITTED ONLINE, DIRECTLY IN TO THE SECURE STUDY DATABASE.

To sign up please visit https://bsrbr.org/database/

Eligibility for registration

- ✓ Diagnosis of Rheumatoid Arthritis
- ✓ Aged 16 Years or over
- Starting eligible biologic treatment ✓

ANTI-TNF originators

adalimumab originator*
Humira

etanercept originator*
Enbrel

infliximab originator*
Remicade

*patients must be biologic, biosimilar & targeted therapy naive to be eligible

BIOSIMILARS

adalimumab biosimilars
Amgevita
Hulio
Hyrimoz
Idacio
Imraldi
Yuflyma

rituximab biosimilars
Rixathon
Ruxience

etanercept biosimilars
Benepali
Erelzi

infliximab biosimilars
Flixabi
Inflectra
Remsima IV
Remsima SC

OTHER TARGETED THERAPIES

baricitinib
Olumiant

certolizumab
Cimzia

tofacitinib
Xeljanz

filgotinib
Jyseleca

tocilizumab
RoActemra

sarilumab
Kevzara

upadacitinib
Rinvoq

Registration within 6 months of the therapy start date* ✓

*For patients already registered who are starting a new therapy, cohort switch request needs to be made within 24 months of therapy start.

Please contact the BSRBR-RA team with any questions

https://bsrbr.org/ 0161 275 1652 biologics.register@manchester.ac.uk

https://twitter.com/BSRBR_RA